Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
61 participants
OBSERVATIONAL
2017-02-23
2021-01-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A: ART initiated during chronic infection
Cohort A will include 36 participants who initiated ART during chronic infection.
Antiretroviral treatment pause
Antiretroviral treatment pause
Cohort B: ART initiated during acute or early infection
Cohort B will include 30 participants who initiated ART during acute/early HIV infection.
Antiretroviral treatment pause
Antiretroviral treatment pause
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antiretroviral treatment pause
Antiretroviral treatment pause
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
NOTE: The term "licensed" refers to a US FDA-approved kit, which is required for all IND studies, or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally.
* Plasma HIV-1 RNA \>1000 copies/mL by any assay obtained prior to initiating ART. NOTE: Documentation or candidate recall is acceptable.
* For Cohort A participants, ART initiated during chronic infection (e.g., more than 6 months after estimated date of infection, or as determined by site investigator, study team, or available medical records).
* For Cohort B, diagnosis of acute HIV infection (AHI) as defined by the criteria listed below.
Fiebig Staging Criteria (must be source documented):
* Fiebig I-II: E/CIA negative, HIV-1 RNA or p24 antigen positive, and negative or indeterminate Western blot, if performed
* Fiebig III-IV: Reactive HIV-1 antibody and negative or indeterminate results on the Western blot or Geenius HIV-1/HIV-2
* Fiebig V: Reactive HIV-1 antibody and positive Western blot or Geenius HIV-1/HIV-2 without p31 band NOTE A: ART must have been initiated more than 10 days after Fiebig I-II diagnosis and less than 90 days after Fiebig V diagnosis to qualify for Cohort B. NOTE B: Candidates who were diagnosed with Fiebig I-II AHI must have had a positive HIV-1 RNA test or subsequently have had a positive Western blot if no positive HIV-1 RNA test was available.
* Receiving continuous ART for at least 2 years and on any NNRTI-, PI-, or INSTI-containing regimen.
NOTE A: ART interruptions of up to 7 days and at least 90 days prior to entry are acceptable.
NOTE B: Within- and between-class changes in ART within the previous 2 years are acceptable.
* For candidates whose ART includes an NNRTI, willingness and ability to change to a PI- or INSTI-containing regimen for at least 4 weeks prior to ART interruption and the local availability of such a regimen.
* Nadir CD4+ cell count ≥200 cells/mm3.
NOTE: Candidate recall or documentation is acceptable.
* CD4+ cell count ≥500 cells/mm3 obtained within 90 days prior to study entry in a US laboratory that has is compliant with Clinical Laboratory Improvement Amendments (CLIA) or its equivalent or in any network approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance (EQA) programs.
* One documented plasma HIV-1 RNA that is below the limit of detection of an FDA-approved assays (limit of detection: 75, 50, 40, or 20 copies/mL) between 12 and 24 months prior to the screening HIV-1 RNA and one documented HIV-1 RNA that is below the limit of detection of the FDA-approved assays (limit of detection: 75, 50, 40, or 20 copies/mL) collected fewer than 12 months prior to the screening HIV-1 RNA.
* Plasma HIV-1 RNA level below the limit of assay quantification within 90 days prior to entry.
* The following laboratory values obtained within 90 days prior to entry by any US laboratory that is compliant with CLIA or its equivalent or in any network approved non-US laboratory that operates in accordance with GCLP and participates in appropriate EQA programs.
Absolute neutrophil count (ANC) ≥750 cells/mm3 Hemoglobin ≥11.0 g/dL for men and ≥10.0 g/dL for women Platelet count ≥100,000/mm3 Creatinine ≤1.5 mg/dL Aspartate aminotransferase (AST) (SGOT) ≤1.5x upper limit of normal (ULN) Alanine aminotransferase (ALT) (SGPT) ≤1.5x ULN
* HCV antibody negative result obtained within 90 days prior to study entry or, if the HCV antibody result is positive, a negative HCV RNA result within 90 days prior to study entry and no positive HCV RNA result within 24 weeks prior to entry.
* Ability and willingness of participant to provide informed consent.
* Willingness to have blood samples collected and stored indefinitely and used for HIV-related research purposes.
* For females of reproductive potential (women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, or women who have not undergone surgical sterilization, specifically hysterectomy, or bilateral oophorectomy and/or bilateral salpingectomy), a negative serum or urine pregnancy test within 48 hours prior to study entry by any clinic or laboratory that has a CLIA certification or its equivalent, or is using a point of care CLIA-waived test, or at any network approved non-US laboratory or clinic that operates in accordance with Good Clinical Laboratory Practices and participates in appropriate external quality assurance programs.
NOTE: Acceptable documentation of hysterectomy and bilateral oophorectomy, bilateral salpingectomy, tubal micro-inserts, partner who has undergone vasectomy, and menopause is participant-reported history.
* All participants must agree to use barrier protection (e.g., condoms, dental dams) for all sexual activity throughout the entire course of the study to prevent HIV transmission.
* All participants must agree not to participate in the conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, or in vitro fertilization). If participating in sexual activity that could lead to pregnancy, the participant/partner must use at least two reliable forms of contraceptives (e.g., condoms, with or without a spermicidal agent; a diaphragm or cervical cap with spermicide; an IUD; hormone-based contraception), with at least one being a barrier method, during the study.
* Site investigator anticipates that a fully active alternative ART regimen could be constructed and would be available in the event of virologic failure on the participant's current ART regimen.
* Absence of either active hepatitis B virus (HBV) infection, indicated by a negative hepatitis B surface antigen (HBsAg) or HBV viral load assays within 90 days prior to entry or known chronic hepatitis B infection based on a previously positive HBV DNA or positive HBsAg without a subsequent positive hepatitis B surface antibody (HBsAb).
Exclusion Criteria
NOTE: A single unconfirmed "blip" (i.e., plasma HIV-1 RNA over limit of detection but \<200 copies/mL) is allowed if preceded and followed by values below the limit of detection and if the blip occurred more than 6 months prior to study entry.
* Currently breastfeeding or plans on breastfeeding during the course of the study or is pregnant.
* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
* Acute or serious illness, in the opinion of the site investigator, requiring systemic treatment and/or hospitalization within 60 days prior to entry.
* Any history of an AIDS-defining illness using the current list on the U.S. Centers for Disease Control and Prevention (CDC)'s website.
* Receipt of any study-defined prohibited medications within 6 months prior to entry.
* Prior history of difficulty establishing venous access or current contraindication for leukapheresis, in the opinion of the site investigator and based on assessments.
* Receipt of any vaccination within 1 week prior to entry.
NOTE: The entry visit must be scheduled to ensure that 1 week has elapsed after any vaccination.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan Li, MD, MMS
Role: STUDY_CHAIR
Brigham and Women's Hospital ACTG CRS
David Smith, MD, MAS
Role: STUDY_CHAIR
University of California San Diego AVRC CRS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
601 University of California, Los Angeles CARE Center CRS
Los Angeles, California, United States
701 University of California, San Diego AntiViral Research Center CRS
San Diego, California, United States
801 University of California, San Francisco HIV/AIDS CRS
San Francisco, California, United States
University of Colorado Hospital CRS (6101)
Aurora, Colorado, United States
Whitman Walker Health CRS (31791)
Washington D.C., District of Columbia, United States
2701 Northwestern University CRS
Chicago, Illinois, United States
Rush Univ. Med. Ctr. ACTG CRS (2702)
Chicago, Illinois, United States
101 Massachusetts General Hospital (MGH) CRS
Boston, Massachusetts, United States
107 Brigham and Women's Hosp. ACTG CRS
Boston, Massachusetts, United States
Washington U CRS (2101)
St Louis, Missouri, United States
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
Rochester, New York, United States
3201 Chapel Hill CRS
Chapel Hill, North Carolina, United States
3203 Greensboro CRS
Greensboro, North Carolina, United States
Pittsburgh CRS (1001)
Pittsburgh, Pennsylvania, United States
3652 Vanderbilt Therapeutics (VT) CRS
Nashville, Tennessee, United States
31443 Trinity Health and Wellness Center CRS
Dallas, Texas, United States
5401 Puerto Rico AIDS Clinical Trials Unit CRS
San Juan, PR, Puerto Rico
31802 Thai Red Cross AIDS Research Centre (TRC-ARC) CRS
Bangkok, Patumwan, Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gianella S, Yu T, Wang R, Ignacio C, Schanz M, Kouyos RD, Caballero G, Gaitan NC, Rawlings S, Kuster H, Metzner KJ, Gandhi RT, Li JZ, Gunthard HF, Smith DM, Chaillon A. Viral and Immune Risk Factors of HIV Rebound After Interruption of Antiretroviral Therapy. J Infect Dis. 2025 Jun 2;231(5):1221-1229. doi: 10.1093/infdis/jiae585.
Li JZ, Melberg M, Kittilson A, Abdel-Mohsen M, Li Y, Aga E, Bosch RJ, Wonderlich ER, Kinslow J, Giron LB, Di Germanio C, Pilkinton M, MacLaren L, Keefer M, Fox L, Barr L, Acosta E, Ananworanich J, Coombs R, Mellors J, Deeks S, Gandhi RT, Busch M, Landay A, Macatangay B, Smith DM; AIDS Clinical Trials Group A5345 Study Team. Predictors of HIV rebound differ by timing of antiretroviral therapy initiation. JCI Insight. 2024 Feb 8;9(3):e173864. doi: 10.1172/jci.insight.173864.
Dube K, Eskaf S, Barr L, Palm D, Hogg E, Simoni JM, Sugarman J, Brown B, Sauceda JA, Henley L, Deeks S, Fox L, Gandhi RT, Smith D, Li JZ. Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. AIDS Res Hum Retroviruses. 2022 Jun;38(6):510-517. doi: 10.1089/AID.2021.0170. Epub 2022 Apr 21.
Diepstra KL, Barr L, Palm D, Hogg E, Mollan KR, Henley L, Stover AM, Simoni JM, Sugarman J, Brown B, Sauceda JA, Deeks S, Fox L, Gandhi RT, Smith D, Li JZ, Dube K. Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. AIDS Res Hum Retroviruses. 2021 Jun;37(6):489-501. doi: 10.1089/AID.2020.0222. Epub 2021 Feb 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACTG A5345
Identifier Type: -
Identifier Source: org_study_id